MarketingMedicalPolicy,Access,Value, andEvidenceConsultingData,Technology,and Media
murmuration of birds

thought leadership

Milestone recognition of HSA and MFDS as WHO-listed authorities advance equitable patient access in Asia-Pacific and globally


The recognition by the World Health Organization (WHO) of Singaporean regulatory agency Health Sciences Authority (HSA), and South Korean regulatory agency Ministry of Food and Drug Safety (MFDS) as WHO-Listed Authorities is a pivotal moment for Asia-Pacific and global health equity. In this market access update we share five key implications of this listing.

Advancing equitable patient access across the Asia-Pacific region and globally

The announcement of HSA and MFDS as WHO-Listed Authorities (WLA) is the first-of-its-kind global recognition of Asian agencies—outside of Japan—meeting international regulatory standards, instilling confidence in the safety and reliability of medical products from these markets.


Global recognition by WHO of the HSA and MFDS Asian market authorities signifies a welcome move towards an evidence-based, more interconnected and transparent patient-focused healthcare ecosystem in the long run.

Sudha Sundaram

Senior Consultant

avatar for Sudha Sundaram - Senior Consultant


Five key patient access implications of the WHO listing of HSA and MFDS:

1. Promoting regulatory convergence
Achieving regulatory harmonization has been a critical goal in the Asia-Pacific (APAC) region, given the diverse levels of regulatory maturity in the region—with some regulators lacking the ability and resources to regularly assess a wide range of emerging health technologies.

While formal harmonization has proven elusive over the years in the APAC region, this WLA ruling brings the different national regulatory authorities in the region closer to regulatory convergence, encouraging mutual guidance and building confidence in regional decisions.

With this, APAC markets can optimize their regulatory capabilities in a way that effectively prioritizes public health, without compromising innovation.

2. Impact on global procurement decision-making
As WLAs, decisions by HSA and MFDS will likely be considered on a par to those from stringent regulatory agencies such as the US Food and Drug Administration and European Medicines Agency.

International as well as national organizations that are responsible for drug and vaccine procurement, such as the Global Drug Fund, often depend on these decisions to guide their product purchasing choices, directly impacting healthcare access for millions of people, especially those in low- and middle-income countries.

3. Enhancing health security
The inclusion of two Asian market authorities as WLAs hopefully marks a promising start, encouraging other Asian markets to build regulatory capacity and incorporate controls to meet international regulatory standards, enabling access to quality-assured health products in the region and beyond.

4. Fostering an open and innovative environment
As more agencies gain global recognition, manufacturers from the APAC region (especially from resource constrained settings with limited regulatory capacity) will have more avenues to get their novel as well as their generic products assessed and accepted onto the global stage. This could help streamline assessment processes for reviewing novel, effective therapeutic options and facilitate timely as well as optimal medical access.

5. Bridging the access time lag
Global and local manufacturers now have more incentive to prioritize product launches in the APAC setting, deviating from a conventional EU/US-first entry approach. This could enable patients in APAC to get early access to novel lifesaving medicines and treatments.


Get in touch for a confidential conversation

For a confidential conversation about addressing your market access challenges, please get in touch with our APAC and global policy, access, value, and evidence experts.

Get in touch



  1. Landmark listing of first three countries as WHO-Listed regulatory Authorities. (2023)
  2. Lim, J.C.W. Strengthening Health Products Regulatory Systems to Enhance Access to Quality Health Products in the Asia-Pacific. Ther Innov Regul Sci 52, 751–754 (2018).
  3. Macé C, Rägo L, Ravinetto R. How the concept of WHO-listed authorities will change international procurement policies for medicines. BMJ Global Health (2022).
  4. Mahoney R, Hotez PJ, Bottazzi ME. Global regulatory reforms to promote equitable vaccine access in the next pandemic. PLOS Glob Public Health, 3(10): e0002482 (2023).

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Fishawack Health website, such as the pages you visit.

For more information, check the cookie statement


Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use.

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.